Gavi has supported measles and rubella immunization programs in over 50 countries since 2000. It has provided over $700 million for measles and rubella vaccines, campaigns, and health systems strengthening. Going forward, Gavi will focus on strengthening routine immunization to ensure gains in measles and rubella control are sustained, while also supporting supplemental immunization activities. Key aspects of Gavi's new strategy include providing vaccines and operational costs for measles second doses and measles-rubella campaigns, and leveraging partnerships to provide targeted technical assistance to countries through its Partners' Engagement Framework.
Dr Seth Berkley presents an update to the Gavi Board meeting in New Delhi, India, covering key developments in the global landscape; how Gavi is working differently to reach zero-dose communities and strengthen primary health care; previous Board decisions; and updates from the Alliance and the Secretariat.
Dr Seth Berkley presents a general update to the Gavi Board meeting in Côte d’Ivoire, reporting on previous Board decisions, global health threats and how the Alliance is gearing up to deliver on the new strategy.
Presentation by Dr Zsuzsanna Jakab, WHO Regional Director for Europe at the South-eastern Europe Health Ministerial Meeting on Immunization in Podgorica, Montenegro, 20 February 2018
Gavi’s CEO Dr Seth Berkley presents an overview of the Vaccine Alliance’s achievements to the Board on 22 June 2016. Topics include results and challenges in the 2011-2015 period, early progress in implementing the 2016-2020 strategy and the role of immunisation on the global agenda.
Dr Seth Berkley presents an update to the Gavi Board meeting in New Delhi, India, covering key developments in the global landscape; how Gavi is working differently to reach zero-dose communities and strengthen primary health care; previous Board decisions; and updates from the Alliance and the Secretariat.
Dr Seth Berkley presents a general update to the Gavi Board meeting in Côte d’Ivoire, reporting on previous Board decisions, global health threats and how the Alliance is gearing up to deliver on the new strategy.
Presentation by Dr Zsuzsanna Jakab, WHO Regional Director for Europe at the South-eastern Europe Health Ministerial Meeting on Immunization in Podgorica, Montenegro, 20 February 2018
Gavi’s CEO Dr Seth Berkley presents an overview of the Vaccine Alliance’s achievements to the Board on 22 June 2016. Topics include results and challenges in the 2011-2015 period, early progress in implementing the 2016-2020 strategy and the role of immunisation on the global agenda.
First presented at the Meningitis Vaccine Project Closure Conference in Addis Ababa in February, Gavi’s CEO Seth Berkley gives a summary of Gavi’s role in reducing the burden of meningitis in Africa.
PLEASE NOTE: THESE SLIDES MAY NOT DISPLAY PROPERLY ONLINE, BUT THEY ARE READABLE IF DOWNLOADED.
October 28, 2018
This one-day conference explored the current pharmaceutical pricing landscape by bringing together leaders from the pharmaceutical industry, policymakers, legal practitioners, and scholars to engage in novel, interdisciplinary discussions to better understand current challenges and articulate best practices to address these issues. Participants assessed the current challenges presented in drug pricing policy, from development to delivery, in both the United States and international context. We also explored and articulated best practices to expand access to medicines and worked toward developing a plan for disseminating these practices more widely.
Dr Seth Berkley presents an update to the Gavi Board meeting in Geneva, Switzerland, covering key developments in the global landscape, strategic progress, previous Board decisions and updates from the Alliance.
The slides contain a brief review of NACP 1 through 4.
Key achievements and challenges of NACP Phase 4 have been mentioned. Further, Key strategies of national strategic plan for elimination of HIV/AIDS 2017-2024 has been discussed.
Gavi CEO Seth Berkley presents key achievements and challenges to the Gavi Board on 10 June 2015. Topics covered include: successful replenishment, new vaccine introductions, coverage and equity, sustainability, the broader immunisation landscape and risk management.
First presented at the Meningitis Vaccine Project Closure Conference in Addis Ababa in February, Gavi’s CEO Seth Berkley gives a summary of Gavi’s role in reducing the burden of meningitis in Africa.
PLEASE NOTE: THESE SLIDES MAY NOT DISPLAY PROPERLY ONLINE, BUT THEY ARE READABLE IF DOWNLOADED.
October 28, 2018
This one-day conference explored the current pharmaceutical pricing landscape by bringing together leaders from the pharmaceutical industry, policymakers, legal practitioners, and scholars to engage in novel, interdisciplinary discussions to better understand current challenges and articulate best practices to address these issues. Participants assessed the current challenges presented in drug pricing policy, from development to delivery, in both the United States and international context. We also explored and articulated best practices to expand access to medicines and worked toward developing a plan for disseminating these practices more widely.
Dr Seth Berkley presents an update to the Gavi Board meeting in Geneva, Switzerland, covering key developments in the global landscape, strategic progress, previous Board decisions and updates from the Alliance.
The slides contain a brief review of NACP 1 through 4.
Key achievements and challenges of NACP Phase 4 have been mentioned. Further, Key strategies of national strategic plan for elimination of HIV/AIDS 2017-2024 has been discussed.
Gavi CEO Seth Berkley presents key achievements and challenges to the Gavi Board on 10 June 2015. Topics covered include: successful replenishment, new vaccine introductions, coverage and equity, sustainability, the broader immunisation landscape and risk management.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
1. www.gavi.org
Gavi’s Measles and Rubella
Programme
M&RI Partners’ Meeting
Michael F Thomas,
Director Vaccine Implementation
September 2017, Washington DC
Reach every child
2. Measles and Rubella support in Gavi
countries by end of 2016
Measles and Measles-Rubella 2nd dose
• 21 countries
• >41 million people immunised
2
#vaccineswork
Measles-Rubella catch-up campaigns*
• 20 countries
• >196 million people immunised
Measles follow-up campaigns
• 6 countries, 9 campaigns
• >132 million people immunised
*with catalytic support for routine introduction of MR 1st dose (provision of VIG)
3. Nonetheless, MCV1 coverage has
stagnated in Gavi countries
3
MCV1
coverage
range:
20-99%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Immunisation coverage in Gavi 73 countries, 2000-2016
MCV1 MCV2 DTP3
Source: Gavi; WHO/UNICEF vaccination coverage estimates, 2016 revision, July 2017; Weighted coverage for Gavi 73 countries
(Date of slide 11 August 2017)
MCV1
78%
MCV2
50%
#vaccineswork
“recommends focusing on improving ongoing immunization systems --
although this may delay reaching measles and rubella elimination goals -- in
order to ensure that gains in measles and rubella control can be sustained”
Measles and Rubella Global Strategic Plan 2012-2020 Midterm Review
4. - Measles control: an important
step on the continuum towards
elimination
- Gavi support should be to
contribute to countries along this
continuum through improved
disease control
- Gavi’s estimated investment for
2016-2020 is ~US$ 1 billion
Gavi’s new Measles and Rubella Strategy:
Best pragmatic return on investment
Increased
country ownership
Programmatic and
financial
sustainability
- Measles is the ‘canary in the coalmine’
- More than 95% of measles deaths occur in countries with low per
capita income and weak health systems
Principles
5
Routine immunisation
strengthening
#vaccineswork
5. Gavi investments in Measles and
Rubella programmes, 2000-2025
#vaccineswork
6
Gavi
expenditure
(US$
million)*
Source: Gavi, the Vaccine Alliance (Financial Forecast v14.0 / Dec 2016).
*Does not include expenditure/investments through the Partners Engagement Framework (Foundational Support or Targeted Country
Assistance)
**2016-2025 includes India and Indonesia MR campaigns in 2017 (US$115M and US$31M resp.)
**
6. Gavi & LCIF Partnership: Social Mobilisation
#vaccineswork
8
38 social mobilisation campaigns by the end of 2017
LCIF Social Mobilisation Campaigns in Gavi-supported Countries
(2013-2017)
Joint Gavi-LCIF SM
activities (13)
Lions-led SM activities
7. Gavi, the Vaccine Alliance strategy, 2016-2020
Renewed focus and shared accountability on Measles and Rubella
4 #vaccineswork
9. Gavi forecasted expenditure for all
programmes, 2000-2015 and 2016-2020
9 #vaccineswork
Source: Gavi, the Vaccine Alliance (Financial Forecast v14.0 / Dec 2016).
US$ 8.1
billion
2016-2020
US$ 9.5
billion
2000-2015
10. PREVIOUS GAVI MEASLES-RUBELLA
PROGRAMME
• Past: Gavi-IFFIm provided US$ 176M to M&RI in 2004-2008
• Current:
• Direct:
• Indirect support:
• HSS Performance-based funding with measles coverage indicator
Gavi has disbursed US$550 million by end 2014. US$ 700
million more forecasted by 2020
11. Gavi supported 50 Measles and Rubella programmes
by end 2016
Measles Second Dose (21 countries)
Country Date
Viet Nam 2007-2011
DPR of Korea 2008-2012
Bangladesh 2012
Cambodia 2012
Eritrea 2012
Gambia 2012
Ghana 2012
Myanmar 2012
Burundi 2013 (Jan)
Zambia 2013 (Jul)
S Tome & Principe 2013 (Oct)
Tanzania 2014 (May)
Burkina Faso 2014 (Oct)
Senegal 2014
Malawi 2015 (Jul)
Rwanda 2015 (Jul)
Sierra Leone 2015 (Sep)
Nepal 2015 (Sep)
Zimbabwe 2015 (Oct)
Mozambique 2015 (Nov)
Papua New Guinea 2016 (Aug)
Measles SIAs (6 countries)
Countries Date
Ethiopia 2013
Nigeria 2013, 2015
DRC* 2013, 2016
Pakistan* 2014
Chad* 2014, 2016
Afghanistan 2015
Measles-Rubella campaigns (20 countries)
Countries Date
Cambodia 2013 (Oct)
Ghana 2013 ( Sep)
Lao PDR VIG for routine
Nepal VIG for routine
Rwanda 2013 (Mar)
Senegal 2013 (Nov)
Viet Nam* 2014 (Aug)
Bangladesh 2014 (Jan)
Tanzania 2014 (Oct)
Burkina Faso 2014 (Nov)
Solomon Islands 2014
Yemen 2014 (Nov)
Myanmar 2015 (Jan)
PNG 2015 (Aug)
Zimbabwe 2015 (Sep)
Cameroon 2015 (Nov)
Gambia 2016 (Apr)
Kenya 2016 (May)
Zambia 2016 (Sep)
Sao Tome e Principe 2016 (Nov)
* In phases
12. Gavi support to enable successful
implementation of Measles and Rubella strategy
1. New Vaccine Support (NVS) for Measles and
Rubella
• Measles and Measles-Rubella vaccines and devices
• Vaccine Introduction Grants and Campaign Operational Costs
2. Partners’ Engagement Framework (PEF)
• Foundational support (FS)
• Targeted country assistance (TCA)
• Strategic Focus Areas (SFA)
3. Health Systems and Immunisation
Strengthening (HSIS)
• Routine immunisation strengthening (MCV1 and MCV2)
• Strengthening of measles, rubella and/or CRS surveillance
#vaccineswork
12
13. 1. NVS for Measles and Rubella
13
• Routine measles 2nd dose and MR 1st & 2nd dose
• Previously Gavi supported measles second dose for 60 months
• Now M2, MR1 and MR2 supported with co-financing
• Wide age initial MR catch-up SIA
• Support of males and females aged 9 months – 14 years; any expansion of
target pop is country financed
• Measles and MR follow up SIA
• Previously only 6 priority countries, now all Gavi eligible countries
• Focus on children 9mo – 5yo; countries can adjust target age within funding
envelope IF evidence provided by the country supports this
• Countries co-finance vaccine costs from 2018 onwards
• Outbreak response fund (through M&RI)
14. 14
2. Partners’ Engagement Framework (PEF): Key principles
• PEF is a new model aimed at purposeful partnerships
• Replaces the Business Plan model applied in 2011-2015
• Funds technical assistance to countries via partners to boost
immunisation
• Seeks to leverage the comparative advantage of partners
15. 15
2. PEF Targeted Country Assistance (TCA): High-level identification
of technical assistance needs takes place during country-led processes
During the JA, partners will discuss:
Summary of key insights generated during the
appraisal of Gavi TCA activities and milestones
Identification of high level needs
Post-Joint Appraisal, partners will discuss:
How has the 2017 technical assistance
progressed?
What adjustments in TA required in 2018?
What areas would benefit from additional support
from other non-core partners?
Menu of TA support
A menu of potential technical assistance activities
is incorporated into the TCA guidance
It provides overview of the types of activities by
programmatic area that EPI program and partners
can consider
Editor's Notes
- Introductory remarks by Michael
Successes of the Gavi programme to date; by the end of 2016, under these 3 historical support windows, Gavi had supported:
For Measles or Measles-Rubella 2nd dose, Gavi had supported 21 countries and over 41 million people immunised
For Measles-Rubella catch-up campaigns, 20 countries and over 196 million people immunised
And for Measles follow-up campaigns, 9 campaigns in 6 countries, with over 132 people immunised.
Despite these Gavi investments and broader comprehensive global efforts from the Measles & Rubella Initiative, MCV1 coverage has remained stagnant at 78% for the past few years; MCV2, while increasing as new countries introduce it, lags behind MCV1 in most of the countries that have introduced it
As indicated by the Midterm Review, as we move forward, we must shift towards a focus on the improvement of routine immunisation systems….
Gavi will have invested approximately US$ 1.5 billion in measles and rubella by 2020, and we seek a pragmatic return on this investment by working on increased country ownership, routine immunisation strengthening, and programmatic and financial sustainability.
We would like to support countries to enable them to achieve sustainable control and elimination when the world is ready for an eradication goal.
This needs a sound health system, centered on attaining a high routine vaccine coverage, complemented by targeted campaigns.
This slides demonstrates the large investment in measles and rubella in 2016-2025 period, amounting to close to US$1.5 billion, a steep increase from the ~US$500k for the 200-2015 period
M&RI is premised on the fact that partnerships are critical to achieving strong coverage of measles and rubella vaccines. Gavi and Lions Clubs International Foundation have been working in partnership to help move the needle on this strategy.
The partnership between LCIF and Gavi is guided by a three-pronged approach that combines resource mobilization, advocacy and partnership awareness, and social mobilization to fight measles around the world.
As the world’s largest service club organization, LCIF has committed to:
Raise USD $30 million during the 2014-2017 period for the purchase of measles and measles-rubella vaccines (MR), supporting introductions and campaigns (SIAs)
This helps leverage an additional USD $30 million contribution through the Gavi Matching Fund in support of Gavi’s measles programs
Tap into LCIF’s global network of donors and volunteers in implementing countries to increase awareness of the benefits of measles vaccines and routine immunisation and advocate for increased funding
Engage local Lion’s clubs in social mobilization activities designed to address barriers affecting low immunisation coverage through community service and locally driven, interpersonal advocacy and communication to increase awareness of and participation in measles and measles-rubella campaigns
The partnership with LCIF is unique because it’s not just LCIF’s incredible financial commitment to beat measles and rubella. But LCIF’s vast network of volunteers who are leaders in their communities are able to raise awareness of the benefits of vaccines, and actually increase demand for many of the measles and rubella campaigns that Gavi supports.
This slide is a snapshot of all the countries LCIF has worked on social mobilization campaigns throughout our partnership.
In countries around the world, LCIF has helped Gavi, UNICEF, WHO, and many other critical partners of M&RI achieve great outcomes for MR campaigns, through SMS messaging, mass media campaigns, door to door outreach, and stakeholder coordination among many other activities. Ministries of Health have noted their ability to reach marginalized communities, increase demand for vaccinations, and build greater awareness within local communities about the benefits of immunization.
- The Gavi strategy for the 2016-2020 period places a renewed focus and aims for shared accountability on Measles and Rubella across the Alliance; CLICK
Strategic Goal 1 in particular focuses on the coverage and equity of immunisation;
As part of this Strategic Goal, there are 4 Measles and Rubella-related indicators as outline on the slide
Strategic Goal on MCV1, which aims for a 5% point increase by 2020
Key Performance Indicator on MCV2, which aims for MCV2 reaching 90% of MCV1 coverage within 24 months of introduction
Key Performance Indicator on SIA coverage, which aims for 90% of SIAs reaching 95% coverage (as validated by survey)
And an indicator on the disease dashboard for measles incidence, to be used for monitoring purposes
Large Gavi investment (1.3b) in measles, which should be protected in next measles strategy.
IMPACT:
Projected by 2020: the current Gavi support totalling US $1.3 billion, countries will have averted more than 2 million future deaths from both measles and rubella.
Worldwide coverage for both routine doses and SIAs contributed to a 72% reduction in measles incidence and an estimated 75% reduction in measles mortality.
From inception to the end of 2014, a total of 25 million children in their second year of life have been vaccinated with measles through the routine programme with Gavi support contributing to 20,000 future deaths averted.
Past Gavi’s investment in M&RI of US$ 176 million contributed to averting 860,000 future deaths.
COST:
By the end of 2014 Gavi had disbursed US$ 338 million for the various components of the measles and rubella programme and US$ 201million to the Measles & Rubella Initiative (M&RI).
For the period 2015-2020, US$ 747 million are forecasted for the support to countries across the 4 components of the programme, bringing to a total of approximately US$ 1.3 billion the total size of Gavi’s investment in measles and rubella by 2020, excluding the funds provided through the Business Plan.
The new Gavi Measles & Rubella programme includes the following components:
Measles Follow-up Campaigns
Measles vaccination campaigns at national or subnational levels, for countries which have not yet introduced MR, with a focus on children up to 5 years of age; noting that the timing, target age range, and geographical scope should be based on epidemiological data. Co-financing of vaccine 2% or 5% if in transition phase
What is the country funding envelope ? 5 year plan, but we don’t have that yet; speak about CEF envelope for 5 years, estimated budget; Sub-national targets in some areas; Country to focus on 9mo-5yo for control purposes; Country to see if thise makes sense from an epidemiological perspective; How much is this over? We don’t want to encourage countries to; we want to encourage countries to make campaigns decision based on epidemiological data
Measles-Rubella (MR) Catch-Up and Follow-up Campaigns
MR catch-up campaign providing MR vaccine for a target population of males and females aged 9 months to 14 years, prior to introducing MR vaccine into the routine national immunisation schedule. Any expansion of the target population would need to be financed by the country.
Support is also available for periodic MR follow-up campaigns, noting that the timing, target age range, and geographical scope should be based on epidemiological data. Co-financing of vaccines 2% or 5% if in transition phase.
Gavi provides support for the above mentioned campaigns in the form of vaccines and associated supplies (i.e. auto-disable syringes, reconstitution syringes and safety boxes). In addition, Gavi provides direct financial support to cover a proportion of the operational costs related to campaigns. The exact level of support available in terms of campaigns will be communicated to countries in due course after the Gavi Board discussion in June 2016.
MCV2 or MR vaccine introduction with co-financing (only for countries who have not yet introduced MR and/or MCV2.)
Routine measles second dose (MCV2) and MR vaccine introduction, requiring countries to co-finance a portion of the vaccine costs according to a specific co-financing formula (and provided that current government financing is not replaced with Gavi funds), as follows:
1) For countries adding a routine measles second dose:
Countries would pay US$ 0.40 for 2 doses of MCV, while Gavi would pay the rest (approximately US$ 0.14-US$ 0.20).
2) For countries introducing MR vaccine (switching from one dose measles to one dose MR vaccine): Countries would pay US$ 0.30 per dose (comparable to the current Weighted Average Price [WAP] of measles vaccine) and Gavi would pay for the rest (approximately similar amount).
3) For countries adding 2 doses of routine MR vaccines:
Countries would pay US$0.60 for 2 doses of MR (comparable to WAP of 2 doses of measles vaccine) and Gavi would pay the rest (approximately similar amount).
For MCV2 or MR vaccine introduction, Gavi will also provide a Vaccine Introduction Grant (VIG) to facilitate activities in the first year of new vaccine introduction. This is a one-time cash grant of US$0.80/child in the birth cohort. Countries are encouraged to identify cross-cutting synergies across VIGs and operational cost support (e.g. communications, training, etc).
Outbreak response (Managed by the Measles & Rubella Initiative [MRI])
Please refer to WHO and UNICEF for the details of this support.